Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Sanofi SA News

    92,15 € +0,71% +0,65 €
    30.04.24 23:00:41 L&S RT aktualisieren | Orderbuch | Mehr Kurse »
    WKN: 920657
    ISIN: FR0000120578
    US-Symbol: SNYNF
    Typ: Aktie
    Werbung

    Attraktive Knock-Outs auf Sanofi SA

    Typ Hebel Bid / Ask WKN
    Call
    		5,1 1,79 € / 1,84 €
    CL7G2W
    Call
    		9,0 1,00 € / 1,05 €
    SN567W
    Typ Hebel Bid / Ask WKN
    Put
    		5,2 1,75 € / 1,80 €
    SH4RDM
    Put
    		8,0 1,12 € / 1,17 €
    SU0ZVW
    Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
    Alle Knock-Outs auf Sanofi SA
    Werbung
    Weiter aufwärts?
    Long Hebel 5,35
    ME4WWM

    Ad-hocs

    15.12.23 - GlobeNewswire
    Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa
    EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa
    11.12.23 - GlobeNewswire
    Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics
    Statement on FTC challenge to proposed license agreement with Maze Therapeutics
    11.12.23 - GlobeNewswire
    Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone
    Sarclisa ® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-​eligible patients with newly diagnosed multiple myeloma versus ...
    07.12.23 - GlobeNewswire
    Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
    Sarclisa ® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
    07.12.23 - GlobeNewswire
    Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology
    R&D Day
    27.11.23 - GlobeNewswire
    Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
    Dupixent ® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for ...
    27.10.23 - GlobeNewswire
    Press Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
    Specialty Care growth, strong launch uptake of Beyfortus ® and ALTUVIIIO ® drive solid Q3 results
    27.10.23 - GlobeNewswire
    Press Release: Sanofi Enters Next Chapter of Play to Win Strategy
    22.10.23 - GlobeNewswire
    Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
    Dupixent ® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
    18.10.23 - GlobeNewswire
    Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM
    TZIELD ® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data ...
    13.10.23 - GlobeNewswire
    Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
    Late-​breaking amlitelimab Phase 2b data presented at EADV show potential best-​in-class profile in atopic dermatitis
    03.10.23 - GlobeNewswire
    Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
    Sanofi announces agreement for potential first-​in-class vaccine against extraintestinal pathogenic E. coli
    26.09.23 - GlobeNewswire
    Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
    Dupixent ® (dupilumab) sBLA for t reatment of e osinophilic e sophagitis in c hildren a ged 1 to 11 accepted for FDA Priority Review
    25.09.23 - GlobeNewswire
    Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A
    19.09.23 - GlobeNewswire
    Press Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change
    31.08.23 - GlobeNewswire
    Press Release: Sanofi announces changes to its Executive Committee
    Sanofi announces changes to its Executive Committee
    03.08.23 - GlobeNewswire
    Press Release: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
    U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus ™ ( nirsevimab-​alip ) to protect infant s against RSV disease
    28.07.23 - GlobeNewswire
    Press release: Online availability of Sanofi’s half-year financial report for 2023
    Online availability of Sanofi’s half-year financial report for 202 3 Paris , July 28, 2023 . Sanofi announces that its half-year financial report for the period ending June 30, 2023 is now ...
    28.07.23 - GlobeNewswire
    Press Release: Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment
    Sanofi to acquire Qunol ® , a fast -growing U.S. brand in the healthy aging segment
    28.07.23 - GlobeNewswire
    Press Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised
    Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised

    Newssuche

    Videos

    30.04.24 -9,41%
    Technical Trading: Sojabohnen Long bis Juli
    Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »